TY - JOUR
T1 - 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO
AU - Bloch, Michael J.
AU - Kirtane, Ajay J.
AU - On behalf of the RADIANCE-HTN Investigators
AU - Azizi, Michel
AU - Mahfoud, Felix
AU - Basile, Jan
AU - Daemen, Joost
AU - Saxena, Manish
AU - Thackeray, Lisa
AU - McGuire, Maureen
AU - Claude, Lisa
AU - Schmieder, Roland E.
AU - Kröpil, Patric
AU - Stegbauer, Johannes
AU - Rump, Christian
AU - Uder, Michael
AU - Ott, Christian
AU - Lucic, Jelena
AU - Ewen, Sebastian
AU - Böhm, Michael
AU - Rommel, Karl Philipp
AU - Fengler, Karl
AU - Höllriegel, Robert
AU - Lurz, Philipp
AU - Elorz, Cristina
AU - Marshall, Andrew John
AU - Faris, Mohamad
AU - Gerber, Robert
AU - D’Souza, Richard
AU - Joseph, Anil
AU - Sharp, Andrew S.P.
AU - Howard, James
AU - Shin, Matthew Shun
AU - Chapman, Neil
AU - Davies, Justin
AU - Beckett, David
AU - Patel, Amit
AU - Edroos, Sadat Ali
AU - Robinson, Nicholas
AU - Vranken, Jeannique
AU - van Zwam, W. H.
AU - Kroon, A. A.
AU - Blankestijn, Peter
AU - Ruiter, Arno
AU - Feyz, Lida
AU - Huang, Pei Hsiu
AU - Costa, Marco
AU - Ferdinande, Bert
AU - Huijskens, Elisabeth
AU - Zeijen, Victor
AU - Lafeber, Melvin
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by −14.5 ± 26.1/−9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and −8.0 ± 24.5/−5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns. (Figure presented.)
AB - Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by −14.5 ± 26.1/−9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and −8.0 ± 24.5/−5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns. (Figure presented.)
UR - http://www.scopus.com/inward/record.url?scp=85204479483&partnerID=8YFLogxK
U2 - 10.1038/s41440-024-01854-w
DO - 10.1038/s41440-024-01854-w
M3 - Article
C2 - 39333663
AN - SCOPUS:85204479483
SN - 0916-9636
VL - 47
SP - 3467
EP - 3472
JO - Hypertension Research
JF - Hypertension Research
IS - 12
ER -